Boston Scientific (NYSE:BSX) Releases Q3 2025 Earnings Guidance

Boston Scientific (NYSE:BSX - Get Free Report) updated its third quarter 2025 earnings guidance on Wednesday. The company provided EPS guidance of 0.700-0.720 for the period, compared to the consensus EPS estimate of 0.698. The company issued revenue guidance of $4.9 billion-$5.0 billion, compared to the consensus revenue estimate of $4.9 billion.

Wall Street Analyst Weigh In

A number of research firms recently commented on BSX. Raymond James Financial increased their target price on shares of Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a research report on Thursday. Royal Bank Of Canada raised their price objective on shares of Boston Scientific from $116.00 to $120.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. Needham & Company LLC reissued a "buy" rating and set a $115.00 price objective on shares of Boston Scientific in a research report on Wednesday, May 28th. Erste Group Bank upgraded shares of Boston Scientific to a "strong-buy" rating in a research note on Thursday, May 8th. Finally, Evercore ISI raised their target price on shares of Boston Scientific from $110.00 to $112.00 and gave the stock an "outperform" rating in a research note on Thursday, April 24th. Two equities research analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $117.50.

Boston Scientific Stock Down 0.1%

Shares of NYSE BSX traded down $0.14 during trading on Friday, reaching $106.07. 5,875,124 shares of the stock were exchanged, compared to its average volume of 7,746,667. The business's 50-day moving average price is $103.58 and its 200 day moving average price is $101.41. Boston Scientific has a twelve month low of $71.88 and a twelve month high of $108.94. The company has a quick ratio of 0.88, a current ratio of 1.45 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $156.92 billion, a price-to-earnings ratio of 63.14, a price-to-earnings-growth ratio of 3.06 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.39%. The firm's quarterly revenue was up 22.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.62 earnings per share. As a group, equities analysts forecast that Boston Scientific will post 2.85 EPS for the current fiscal year.

Insider Activity at Boston Scientific

In related news, EVP John Bradley Sorenson sold 4,572 shares of the company's stock in a transaction on Monday, May 5th. The shares were sold at an average price of $104.54, for a total value of $477,956.88. Following the sale, the executive vice president directly owned 18,705 shares of the company's stock, valued at $1,955,420.70. This represents a 19.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Michael F. Mahoney sold 164,443 shares of the stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $103.69, for a total transaction of $17,051,094.67. Following the sale, the chief executive officer directly owned 1,476,882 shares in the company, valued at $153,137,894.58. This trade represents a 10.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 457,144 shares of company stock valued at $47,296,288. Insiders own 0.50% of the company's stock.

Hedge Funds Weigh In On Boston Scientific

A hedge fund recently raised its stake in Boston Scientific stock. Brighton Jones LLC boosted its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 0.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 27,376 shares of the medical equipment provider's stock after buying an additional 226 shares during the period. Brighton Jones LLC's holdings in Boston Scientific were worth $2,445,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.